Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117506 · ClinicalTrials.gov registry record
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
A clinical trial of Cardiovascular Diseases and Coronary Artery Disease, sponsored by CardioDx.
- Completed
- Registry status
- 581
- Enrollment target
- 7
- Study locations
NCT01117506 is a study of Cardiovascular Diseases and Coronary Artery Disease that has completed, run by CardioDx. The registered enrollment target is 581 participants, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT01117506, a study of Cardiovascular Diseases and Coronary Artery Disease, has completed, sponsored by CardioDx.
- COMPLETED
- Registry status
- 581 participants
- Enrollment target
- 7
- Study locations
Study Summary
To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease. The study will evaluate the clinical utility of a gene expression test Corus CAD (Age, Sex, Gene Expression Score - ASGES) in subjects referred for myocardial perfusion imaging (MPI) work-up for suspected obstructive atherosclerotic coronary artery disease (CAD). The Corus CAD (ASGES) is a gene expression test that quantify the expression of multiple genes from circulating peripheral blood cells to detect the presence of clinically significant obstructive CAD in patients with chest pain.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Corus CAD (ASGES)
Study Locations (7)
California
- Long Beach Memorial Hospital - Long Beach
- Sutter Roseville Medical Center - Roseville
Colorado
- Pikes Peak Cardiology - Boulder
Kansas
- Midwest Cardiology Associates - Overland Park
Missouri
- St. Luke's Hospital - Kansas City
Pennsylvania
- Berks Cardiologists, Ltd - Wyomissing
Virginia
- Cardiovascular Associates of Virginia - Midlothian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01117506
The ClinicalTrials.gov registry entry for NCT01117506 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 581 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower). The listed sponsor is CardioDx, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Corus CAD (ASGES) is the first listed.
NCT01117506 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Kansas.
Frequently Asked Questions
What is clinical trial NCT01117506 about?
NCT01117506 is a clinical study titled "Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)". To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease. The study will evaluate the clinical utility of a gene expression test Corus CAD (Age, Sex, Gene Expression Score - ASGES) in subjects referre...
What is the current status of trial NCT01117506?
This trial is currently completed. The enrollment target is 581 participants. The study started on 2010-04. Estimated completion is 2012-05.
What conditions does trial NCT01117506 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Coronary Artery Disease, Chest Pain, Coronary Heart Disease, Angina Pectoris.
What interventions are being tested in trial NCT01117506?
The interventions under investigation include: Corus CAD (ASGES) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01117506?
This trial is sponsored by CardioDx, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01117506 being conducted?
This trial has 7 study locations across California, Colorado, Kansas, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
RECRUITING
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.